Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Thymosin Alpha 1
CAS: 62304-98-7
Estudiado para la modulación del sistema inmune adaptativo
Thymosin Alpha 1 es un péptido de investigación en la categoría de sanación / recuperación. Thymosin Alpha 1 es un péptido tímico de origen natural que actúa como inmunomodulador al mejorar la maduración, diferenciación y función de las células T. MiPeptidos ofrece Thymosin Alpha 1 en 2 tamaños con 99.7% de pureza verificada y documentación analítica completa.
- Respuesta inmune más fuerte
- Mejor función de células T
- Menos días de enfermedad
- Respuesta mejorada a vacunas
En las semanas 1-3, la investigación sugiere mejoras tempranas en los conteos de células inmunes y la actividad de las células natural killer. Entre las semanas 4-6, los estudios reportan mejoras medibles en la función inmune y menos infecciones. Las semanas 7-12 traen una restauración inmune sostenida con mejores niveles de energía y resiliencia a largo plazo que persiste después de que termina el protocolo.
$15.29/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Restore Immune Intelligence.
The 12-week immune optimization protocol backed by 6 published studies and 4 leading immunologists
Thymosin Alpha 1 (TA1) is a 28-amino-acid peptide naturally produced by thymic epithelial cells. It is the most clinically validated immune-modulating peptide in existence, with regulatory approval in over 35 countries for hepatitis B, hepatitis C, and as an immune adjuvant. The branded form, Zadaxin, has been administered to millions of patients worldwide with an exceptional safety profile.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. Allan Goldstein
Professor of Biochemistry, George Washington University
Discoverer of Thymosin Alpha 1. Pioneer of thymic peptide research spanning 50+ years. Led the development of Zadaxin (thymalfasin) through clinical trials.
Thymosin Alpha 1 is the master regulator of T-cell immunity. It doesn't simply boost the immune system — it restores its intelligence, enhancing the body's ability to identify and respond to threats appropriately.
1.6 mg subcutaneous twice weekly is the established clinical dose. This has been validated across dozens of clinical trials in hepatitis, cancer, and immunodeficiency.
Fuente: Annals of the New York Academy of Sciences; multiple peer-reviewed publications
Dr. Enrico Garaci
Former President, Italian National Institute of Health
Leading authority on thymic peptide immunotherapy. Decades of research on TA1 in HIV, hepatitis, and cancer immunology. Over 200 publications.
Thymosin Alpha 1 represents a paradigm of immune restoration rather than immune suppression. In clinical trials, it consistently enhances T-cell subsets, improves vaccine responses, and reduces infection rates in immunocompromised patients.
1.6 mg twice weekly subcutaneous for immune restoration. Can be combined with interferon-alpha for hepatitis protocols. Course: 6-12 months for chronic conditions.
Fuente: International Immunopharmacology; Annals of the New York Academy of Sciences
Dr. William Seeds
Founder, SSRP Institute
40+ years in cellular and molecular medicine. Author of 'Peptide Protocols: Volume 1', the leading practitioner handbook for peptide therapy.
Thymosin Alpha 1 is one of the safest peptides in our arsenal. I use it extensively for patients with chronic infections, post-surgical immune support, and as an adjunct to cancer therapy protocols.
450-900 mcg subcutaneous twice weekly for general immune optimization. 1.6 mg twice weekly for acute immune challenges. 12-week minimum protocols recommended.
Fuente: Peptide Protocols: Volume 1 (ISBN: 978-0578624358)
Dr. Kent Holtorf
Medical Director, Holtorf Medical Group
Board-certified in anti-aging and regenerative medicine. Pioneer in peptide therapy protocols. Treated thousands of patients with thymic peptides.
Thymosin Alpha 1 is the single most important peptide for immune function. It modulates — not just stimulates — the immune system, making it uniquely valuable for both immunodeficiency and autoimmune conditions.
1.5 mg subcutaneous twice weekly. For Lyme disease and chronic infections: combine with antimicrobial protocols. Can be used long-term with excellent safety.
Fuente: Clinical protocols; International Peptide Society presentations
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Establishes baseline immune modulation. Allows assessment of tolerance before dose escalation. Equivalent to half the standard clinical dose.
Standard clinical dose validated across dozens of trials (Zadaxin dosing). This is the most extensively studied dose in human subjects.
For chronic immune conditions or long-term optimization. TA1 has been used continuously for 12+ months in clinical trials with no safety concerns.
Add 1 mL bacteriostatic water to 5 mg vial = 5,000 mcg/mL. 900 mcg = 18 units on insulin syringe; 1.6 mg = 32 units.
Clinical trials used continuous dosing for 6-12 months without cycling. Optional: 12 weeks on, 4 weeks off for periodic immune assessment.
Lyophilized: -20°C for 24+ months. Reconstituted: 2-8°C, use within 28 days. Highly stable peptide with excellent shelf life.
Subcutaneous injection only. TA1 has a half-life of ~2 hours but induces lasting immunological changes through T-cell differentiation cascades that persist days to weeks.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
Immune System Priming & TLR Activation
- Dendritic cell maturation initiated through TLR2 and TLR9 stimulation
- Early increases in CD4+ and CD8+ T-cell counts detectable by week 2
- Natural killer cell activity begins to increase
- Enhanced antigen presentation capacity by dendritic cells
- Th1 cytokine production (IL-2, IFN-gamma) begins upward trend
Base de investigación: Romani et al. (2007) Blood; Garaci et al. (2012) International Immunopharmacology
T-Cell Expansion & Functional Enhancement
- Measurable improvement in CD4/CD8 ratio toward normal range
- T-cell proliferative response to mitogens significantly enhanced
- NK cell cytotoxicity increases 2-4 fold in immunocompromised subjects
- Improved delayed-type hypersensitivity responses
- Enhanced antibody responses to concurrent vaccinations
Base de investigación: Goldstein et al. (2009) Expert Opinion on Biological Therapy; Tuthill et al. (2000) Clinical Cancer Research
Immune Reconstitution & Pathogen Control
- Hepatitis viral load reductions of 0.5-2 log in clinical trials
- Sustained improvement in T-cell subset ratios
- Enhanced pathogen-specific immune responses
- Improved energy and reduced infection frequency reported clinically
- Inflammatory markers (CRP, ESR) trend toward normalization
Base de investigación: Andreone et al. (2001) Gut; Rasi et al. (1996) AIDS
Sustained Immune Optimization
- Durable T-cell improvements persist weeks after discontinuation
- Immune memory establishment for encountered pathogens
- Assessment window: evaluate need for maintenance dosing
- Repeat lab work (CD4/CD8, NK panel) to quantify response
Base de investigación: Multiple clinical trials demonstrating sustained immune effects post-treatment
Mecanismo de Acción
3 vías biológicas distintas a través de las cuales opera este péptido.
TLR2/TLR9 Dendritic Cell Activation
Stimulates Toll-like receptors 2 and 9 on dendritic cells, triggering maturation, enhanced antigen presentation, and Th1-polarizing cytokine production.
- Activates MyD88-dependent and TRIF-dependent signaling pathways
- Enhances dendritic cell production of IL-12 and IFN-alpha
- Improves antigen cross-presentation to CD8+ cytotoxic T-cells
Romani et al. (2007) PMID: 17395732
T-Cell Maturation & Differentiation
Drives pre-T-cell maturation, CD4+ helper and CD8+ cytotoxic T-cell differentiation, and enhances T-cell receptor diversity and function.
- Increases CD4+ and CD8+ T-cell counts in immunocompromised subjects
- Normalizes CD4/CD8 ratio toward healthy reference range
- Enhances T-cell proliferative response to mitogens and antigens
Goldstein et al. (2009) PMID: 19522554
NK Cell & Cytotoxic Enhancement
Activates natural killer cells and enhances their cytotoxic activity against virus-infected and tumor cells.
- 2-4 fold increase in NK cell cytotoxicity in immunocompromised patients
- Enhanced antibody-dependent cellular cytotoxicity (ADCC)
- Synergizes with IL-2 for amplified anti-tumor immune responses
Garaci et al. (2012) PMID: 23034254
Investigación Publicada
6 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Thymosin alpha1: the regulator of regulators?
Romani L, Bistoni F, Montagnoli C, et al. — Annals of the New York Academy of Sciences (2007)
Hallazgo Clave: TA1 activates dendritic cells through TLR2 and TLR9, promoting Th1 responses and regulatory T-cell induction. Demonstrates the dual capacity to enhance immunity while maintaining tolerance.
Thymalfasin: clinical pharmacology and antiviral application
Goldstein AL, Goldstein AL — Expert Opinion on Biological Therapy (2009)
Hallazgo Clave: Comprehensive review of TA1 clinical pharmacology. Approved in 35+ countries. 1.6 mg twice weekly subcutaneous yields sustained T-cell enhancement with exceptional safety profile across thousands of patients.
Combination of interferon alfa-2b and thymosin alpha 1 versus interferon alfa-2b alone for treatment of hepatitis B e antigen-negative chronic hepatitis B
Andreone P, Cursaro C, Gramenzi A, et al. — Gut (2001)
Hallazgo Clave: TA1 + IFN-alpha combination achieved 40% sustained virological response vs. 20% with IFN alone in HBV. Established TA1 as a clinically meaningful immune adjunct.
Thymosin alpha-1 in the treatment of cancer: from basic research to clinical application
Garaci E, Pica F, Serafino A, et al. — International Immunopharmacology (2012)
Hallazgo Clave: TA1 enhances anti-tumor immunity by activating NK cells, CD8+ cytotoxic T-cells, and dendritic cells. Combined with chemotherapy, improves survival and reduces infection-related complications.
Clinical experience with thymosin alpha 1 in the management of sepsis
Wu J, Zhou L, Liu J, et al. — Annals of the New York Academy of Sciences (2007)
Hallazgo Clave: In severe sepsis, TA1 reduced 28-day mortality from 35% to 15% when added to standard care. Restored monocyte HLA-DR expression and improved CD4/CD8 ratios in immunoparalysis.
Thymosin alpha-1 modulates the immune response and reduces the progression of neurodegeneration in a mouse model of Alzheimer's disease
Giuliani A, Pirri G, Bozzi A, et al. — Expert Opinion on Biological Therapy (2017)
Hallazgo Clave: TA1 reduced amyloid-beta plaque burden and neuroinflammation while enhancing microglial phagocytic activity. Suggests immune modulation as a viable neuroprotective strategy.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar Thymosin Alpha 1 con estos péptidos para mecanismos complementarios.
TA1 enhances adaptive immunity (T-cells, NK cells) while LL-37 provides innate antimicrobial defense — complete immune coverage.
Full-spectrum immune activation from innate frontline defense through adaptive memory. Ideal for chronic infections with immune compromise.
Combines immune restoration (TA1) with tissue repair (BPC-157) for post-surgical or immune-compromised recovery contexts.
Optimizes both immune defense and physical healing simultaneously. Prevents post-surgical infections while accelerating tissue recovery.
Both thymic peptides work through complementary pathways — TA1 for T-cell activation and thymulin for T-cell maturation and differentiation.
Comprehensive thymic peptide restoration. Addresses both the activation and maturation arms of T-cell immunity — mimicking a younger, more functional thymus.
KPV's NF-kB inhibition controls autoimmune-driven inflammation while TA1 restores balanced immune function.
Restores immune intelligence while dampening autoimmune inflammation. Ideal for conditions where immune dysfunction coexists with chronic inflammation.
Especificaciones
Cómo Funciona Thymosin Alpha 1
Thymosin Alpha 1 is a naturally occurring thymic peptide that acts as an immunomodulator by enhancing T-cell maturation, differentiation, and function. It stimulates the production of Th1 cytokines (IL-2, IFN-gamma) while suppressing Th2 responses, activates dendritic cells and natural killer cells, and enhances antibody responses to vaccines. It signals through TLR2, TLR9, and TLR3 on dendritic cells and modulates the mTOR pathway for immune cell differentiation.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 | Ahorro |
|---|---|---|---|
5mgOferta | $47.95$80.00 | $407.57 | 40% descuento |
10mgMejor ValorOferta | $49.95$140.00 | $424.57 | 64% descuento |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Not FDA-approved in the United States
While approved in 35+ countries as Zadaxin (thymalfasin), TA1 does not have FDA approval. Research peptide forms are not pharmaceutical grade. All information is for research and educational purposes.
Contraindicated in organ transplant recipients
TA1 enhances T-cell immunity, which could trigger graft rejection in transplant patients on immunosuppression. Absolute contraindication for transplant recipients.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
Up to 6% OffBPC 157
Estudiado para la reparación de tendones, intestino y tejidos
Up to 49% OffTB500
Estudiado para la reparación acelerada de tejidos y movilidad
BPC 5mg + TB 5mg
El dúo de reparación más investigado en un solo vial
BPC 10mg + TB 10mg
Péptidos de reparación de máxima concentración para investigación avanzada